PRI peptide is naturally processed from either HNE or PRO3 in HLAA*0201-positive individuals
. | . | . | . | . | . | . | . | . | . | . | . | . | . | CTL activity, % . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | HLA type . | . | . | . | . | Phenotype, % . | . | PR1 tetramer+ cells in CD8, % . | . | . | PR1, μM/mL . | . | . | HNE, μg/mL . | . | KLH, μg/mL . | . | |||||||||||
| . | A . | B . | Cw . | DRβ1 . | DQβ1 . | CD4 . | CD8 . | Before . | HNE . | PRO3 . | 0.1 . | 1.0 . | 10 . | 1.0 . | 1.0 + K562 . | 0 . | 10 . | |||||||||||
| D21 | 0201,30 | 18,44 | 0501,— | 04,13 | 03,06 | 71.3 | 25.7 | 0.1* | 0.29* | 1.17* | 3.32* | — | 3.54* | — | — | — | — | |||||||||||
| D22 | 01,0201 | 08,40 | 03,07 | 0101,0701 | 0501,02 | 22.4 | 76.4 | — | 0.01 | 0.0 | — | NR | NR | 12.4 | 0 | 2.5 | 4.3 | |||||||||||
| D23 | 0201,68 | 07,8101 | 1505,18 | 13,— | 05,06 | 5.3 | 94.4 | — | 0.02 | 0.04 | — | NR | NR | — | — | — | — | |||||||||||
| D24 | 0201,3101 | 07,35 | 04,07 | 0407,1501 | 0301,06 | 13.5 | 86.2 | — | 0.01 | 0.11* | — | NR | NR | 50.4* | 20.4* | 0 | 0 | |||||||||||
| D25 | 0201,30 | 13,4501 | 0602,1601 | 07,— | 02,— | 23.4 | 77.4 | 0.02* | 0.55* | 0.40* | — | Inc | Inc | 31.4* | 26.3* | 6.0 | 4.0 | |||||||||||
. | . | . | . | . | . | . | . | . | . | . | . | . | . | CTL activity, % . | . | . | . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. . | HLA type . | . | . | . | . | Phenotype, % . | . | PR1 tetramer+ cells in CD8, % . | . | . | PR1, μM/mL . | . | . | HNE, μg/mL . | . | KLH, μg/mL . | . | |||||||||||
| . | A . | B . | Cw . | DRβ1 . | DQβ1 . | CD4 . | CD8 . | Before . | HNE . | PRO3 . | 0.1 . | 1.0 . | 10 . | 1.0 . | 1.0 + K562 . | 0 . | 10 . | |||||||||||
| D21 | 0201,30 | 18,44 | 0501,— | 04,13 | 03,06 | 71.3 | 25.7 | 0.1* | 0.29* | 1.17* | 3.32* | — | 3.54* | — | — | — | — | |||||||||||
| D22 | 01,0201 | 08,40 | 03,07 | 0101,0701 | 0501,02 | 22.4 | 76.4 | — | 0.01 | 0.0 | — | NR | NR | 12.4 | 0 | 2.5 | 4.3 | |||||||||||
| D23 | 0201,68 | 07,8101 | 1505,18 | 13,— | 05,06 | 5.3 | 94.4 | — | 0.02 | 0.04 | — | NR | NR | — | — | — | — | |||||||||||
| D24 | 0201,3101 | 07,35 | 04,07 | 0407,1501 | 0301,06 | 13.5 | 86.2 | — | 0.01 | 0.11* | — | NR | NR | 50.4* | 20.4* | 0 | 0 | |||||||||||
| D25 | 0201,30 | 13,4501 | 0602,1601 | 07,— | 02,— | 23.4 | 77.4 | 0.02* | 0.55* | 0.40* | — | Inc | Inc | 31.4* | 26.3* | 6.0 | 4.0 | |||||||||||
CD3+ T cells from 5 healthy individuals (donors 21-25) were stimulated 4 times with HNE- or PRO3-loaded DCs. CD8+ T-cell responses to PR1 peptide are shown as stimulation indices (see “Cold target inhibition assay” for details). NR indicates no response;—, not done (because of insufficient cell numbers, not all peptides were tested in all cases); and Inc, high IFN-γ mRNA copy number but inconclusive because of high background to control. CTL assay data were obtained at 10:1 E/T ratio. Representative data are from 3 independent experiments are shown.
Significantly positive results.